These tests will be carried out from September 2024 to August 2025. The drug works by disabling a protein associated with a gene that inhibits tooth growth.
Previous tests on animals such as ferrets and mice were successful and showed no significant side effects.
The first phase of the clinical trial will involve thirty men, aged 30 to 64, who are missing at least one molar.
The medication will be administered intravenously. After this stage, tests will continue on children aged 2-7 with congenital dental problems, as well as people who have toothlessness and partial tooth loss due to environmental factors.
The research is conducted by Katsu Takahashi, an expert in dentistry and molecular biology who has been working on tooth restoration methods since 2005.
He is confident that the new technology will find wide application and allow people of all ages to repair their teeth. The commercial launch of the drug is expected to be made in 2030 at the latest.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
